DOP Session 6

  • 17:20-18:20 Digital Oral Presentation Session 6 - Optimisation of biologic therapies
    Room: Lehar 1-3, Ground Floor, Congress Centre
    Chairs:
    Axel Dignass, Frankfurt, Germany
    Paula Ministro, Viseu, Portugal
      17:20-17:26 DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s Disease: Data from the LOVE-CD trial
    S. Berends1, 2, M. Löwenberg2, F. Baert3, R. Mathôt1, E. Clasquin2, C. Van Der Woude4, F. Hoentjen5, P. Bossuyt6, D. Franchimont7, T. Rispens8, 9, A. De Vries9, S. Vermeire10, G. D'Haens2
    1. Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, Netherlands
    2. Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, Netherlands
    3. AZ Delta Roeselare-Menen, Gastroenterology, Roeselare-Menen, Belgium
    4. Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands
    5. Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, Netherlands
    6. Imelda GI Clinical Research Center, Gastroenterology, Bonheiden, Belgium
    7. Erasme Hospital, Gastroenterology, Brussels, Belgium
    8. Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam, Netherlands
    9. Sanquin Diagnostic Services, Biologicals Lab, Amsterdam, Netherlands
    10. University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium
      17:26-17:32 DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s Disease: Pharmacokinetic-pharmacodynamic analysis of TAILORIX
    E. Dreesen1, G. D'Haens2, F. Baert3, B. Pariente4, Y. Bouhnik5, J. vander Woude6, J. Moreau7, D. Laharie8, S. Vermeire9, 10, A. Gils1
    1. KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
    2. Academic Medical Centre, Amsterdam, Netherlands
    3. AZ Delta, Roeselare, Belgium
    4. Hospital Claude Huriez, Lille, France
    5. Hospital Beaujon, Clichy, France
    6. Erasmus MC, Rotterdam, Netherlands
    7. CHU, Toulouse, Belgium
    8. Hospital Haut-Lévêque, Bordeaux, France
    9. University Hospitals Leuven, Department of Gastroenterology and
    Hepatology, Leuven, Belgium
    10. KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium
      17:32-17:38 DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with Inflammatory Bowel Disease
    A. Yarur1, A. Bruss1, C. Fox1, P. Beniwal-Patel1, A. Patel1, B. Berens1, S. Naik2, D. Stein1
    1. Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, United States
    2. Prometheus Laboratories, San Diego, United States
      17:38-17:44 DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective study
    D. Tarabar1, K. El Jurdi2, O. Yvellez2, Z. Milenkovic1, S. Petrovic1, B. Subotic1, T.P. Brocic1, I. Brcerevic1, O. Latinovic3, D.T. Rubin2 
    1. Military Medical Academy, Belgrade, Serbia 
    2. University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States 
    3. Clinical Center Vojvodina, Novi Sad, Serbia
      17:44-17:50 DOP050: Influence of disease location on vedolizumab efficacy in Inflammatory Bowel Disease: A real-life multicentre experience
    S. Pestour1, S. Nancey2, A.L. Charlois2, B. Bonaz1, B. Flourie2, G. Boschetti2, N. Mathieu1
    1. Grenoble Alpes University Hospital, University Clinic of Hepato-Gastroenterology, Grenoble, France
    2. Lyon Sud University Hospital, Department of Gastroenterology, Lyon, France
      17:50-17:56 DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s Disease but not Ulcerative Colitis: A multi-centre consortium analysis
    D. Faleck1, A. Winters1, S. Chablaney1, P. Shashi2, J. Meserve3, A. Weiss4, S. Aniwan5, J.L. Koliani-Pace6, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch7, M. Luo7, M. Bohm8, S. V Sagi8, M. Fischer8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel6, B. Shen2, W.J. Sandborn3, S. Kane5, E.V. Loftus5, B.E. Sands1, J.-F. Colombel1P.S. Dulai3, R. Ungaro1
    1. Icahn School of Medicine at Mount Sinai, New York, United States
    2. Cleveland Clinic Foundation, Cleveland, United States
    3. University of California - San Diego, La Jolla, United States
    4. Montefiore Medical Center, New York, United States
    5. Mayo Clinic, Rochester, United States
    6. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    7. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States
    8. Indiana University, Indianapolis, United States
    9. New York University (NYU), New York, United States
    10. North Shore University Hospital, Manhasset, United States
    11. Lenox Hill Hospital, New York, United States
    12. University of Mississippi, Jackson, United States
      17:56-18:02 DOP052: Vedolizumab versus ustekinumab for Crohn's Disease: Comparative effectiveness in a real-life observational cohort study (ICC Case Series)
    V. Biemans1, 2 , C. van der Woude3, A. van der Meulen - de Jong4, G. Dijkstra5, N. de Boer6, B. Oldenburg7, C. Ponsioen8, A. de Vries3, D. Wintjens2, F. Hoentjen9, M. Pierik2, Dutch Initiative on Crohn and Colitis (ICC) 
    1. Radboudumc, Nijmegen, Netherlands 
    2. Maastricht University Medical Center (MUMC), Maastricht, Netherlands 
    3. Erasmus Medical Center, Rotterdam, Netherlands 
    4. Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, Netherlands 
    5. University Medical Center Groningen, Groningen, Netherlands 
    6. VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, Netherlands 
    7. University Medical Centre Utrecht, Utrecht, Netherlands 
    8. Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands 
    9. Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands

      18:02-18:08 DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: A multicentre consortium propensity score–matched analysis
    D. Hudesman1, S. Chang1, P. Shashi2, A. Winters3, S. Chablaney3, J. Meserve4, A. Weiss5, S. Aniwan6, D. Faleck3, J.L. Koliani-Pace7, G. Kochhar2, B. Boland4, S. Singh4, R. Hirten3, E. Shmidt3, K. Lasch8, M. Luo8, M. Bohm9, S. V Sagi9, M. Fischer9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, S. Kane6, E.V. Loftus6, B.E. Sands3, W.J. Sandborn4, J.-F. Colombel3P.S. Dulai4
    1. New York University (NYU), New York, United States
    2. Cleveland Clinic Foundation, Cleveland, United States
    3. Icahn School of Medicine at Mount Sinai, New York, United States
    4. University of California - San Diego, La Jolla, United States
    5. Montefiore Medical Center, New York, United States
    6. Mayo Clinic, Rochester, United States
    7. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    8. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States
    9. Indiana University, Indianapolis, United States
    10. North Shore University Hospital, Manhasset, United States
    11. Lenox Hill Hospital, New York, United States
    12. University of Mississippi, Jackson, United States
      18:08-18:14 DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s Disease: An exploratory analysis of the GEMINI 2 and GEMINI 3 studies
    B.E. Sands1, G. Van Assche2, D. Tudor3, T. Tan4
    1. Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States
    2. University Hospitals Leuven and TARGID, Division of Gastroenterology and Hepatology, Leuven, Belgium
    3. Takeda Pharmaceuticals International AG, Zurich, Switzerland
    4. Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland